The U.S. Food and Drug Administration (FDA) has approved tavapadon (Juvmo) for the treatment of Parkinson disease in adults. Juvmo is an oral, once-daily selective partial agonist at dopamine D1 and D5 receptors. It was studied without levodopa in early disease and as an adjunct to levodopa in patients with motor fluctuations.
The approval adds a new dopamine agonist option for motor symptom control. Earlier dopamine agonists primarily target D2 and D3 receptors, whereas tavapadon selectively activates D1 and D5 receptors. This difference is pharmacologically important, but it should not be interpreted as proof of superior tolerability because tavapadon has not been compared directly with other dopamine agonists.
Mechanism of action
Tavapadon is a selective partial agonist at dopamine D1 and D5 receptor subtypes. The FDA-approved label describes this receptor activity but does not establish that receptor selectivity eliminates the class-related risks of dopamine agonists.
Dosing and administration
Juvmo is taken once daily with or without food. Treatment begins at 0.25 mg once daily and is titrated over 40 days to a maintenance dose of 5 mg once daily. Based on response and tolerability, the dose may then be increased by 5 mg at intervals of approximately 15 days to a maximum of 15 mg once daily. Longer intervals may be used when needed.
| Treatment period |
Daily dose |
| Days 1 to 4 | 0.25 mg |
| Days 5 to 8 | 0.5 mg |
| Days 9 to 12 | 0.75 mg |
| Days 13 to 16 | 1 mg |
| Days 17 to 20 | 1.5 mg |
| Days 21 to 24 | 2.25 mg |
| Days 25 to 40 | 3 mg |
| Day 41 and thereafter | 5 mg maintenance; may increase to 10 mg and then 15 mg |
Tavapadon is primarily metabolized by CYP3A. Strong or moderate CYP3A inhibitors should be avoided during titration, and strong CYP3A inducers should be avoided during titration and maintenance. During maintenance, the label calls for reduced dosing frequency with strong or moderate CYP3A inhibitors and increased frequency with long-term moderate CYP3A inducers. Tavapadon is also a CYP3A inducer and inhibits CYP2C8 and BCRP, so doses of sensitive substrates may need adjustment.
Evidence supporting approval
The Phase 3 TEMPO program evaluated tavapadon in adults with early Parkinson disease who were not taking levodopa (a stable MAO-B inhibitor was allowed) and in adults with motor fluctuations despite levodopa. All three randomized, double-blind, placebo-controlled trials lasted 27 weeks, with efficacy assessed at Week 26.
| Trial |
Population and treatment |
Primary efficacy result at Week 26 |
| TEMPO 1 |
529 adults with early Parkinson disease; fixed-dose tavapadon 5 mg or 15 mg versus placebo |
MDS-UPDRS Part II change: -1.6 and -1.7 with tavapadon versus +0.9 with placebo; p<0.0001 for both doses |
| TEMPO 2 |
304 adults with early Parkinson disease; flexible-dose tavapadon 5 to 15 mg versus placebo |
MDS-UPDRS Part II change: -1.5 with tavapadon versus 0.0 with placebo; difference -1.5 points; p=0.0007 |
| TEMPO 3 |
507 adults with motor fluctuations on a fixed levodopa dose; tavapadon 5 to 15 mg versus placebo |
Daily ON time without troublesome dyskinesia increased 1.7 hours versus 0.6 hour; difference 1.1 hours; p<0.0001 |
Early Parkinson disease
TEMPO 1 and TEMPO 2 used the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part II (MDS-UPDRS Part II), a 13-item measure of motor aspects of daily living (scored 0 to 52; lower scores indicate improvement). In TEMPO 1, both fixed doses improved scores relative to placebo (least-squares mean differences of -2.5 and -2.6 points). In TEMPO 2, flexible dosing from 5 to 15 mg also improved scores relative to placebo.
Parkinson disease with motor fluctuations
In TEMPO 3, patients continued a stable levodopa regimen and added tavapadon or placebo. Tavapadon increased daily ON time without troublesome dyskinesia by 1.7 hours from baseline, compared with 0.6 hour for placebo. Daily OFF time decreased by 1.9 hours with tavapadon and by 0.9 hour with placebo, a least-squares mean difference of -0.9 hour (p=0.0006).
Longer term findings
Participants who completed a pivotal trial could enter a 58-week open-label extension (TEMPO 4, described by the Michael J. Fox Foundation as ongoing). AbbVie reported sustained efficacy through a total of 85 weeks. Among participants treated for 85 weeks, 96 of 103 (93%) using tavapadon with levodopa had not increased their levodopa dose, and 257 of 273 (94%) receiving tavapadon without levodopa had not started levodopa. These figures are company-reported data on file and come only from participants who reached 85 weeks. They are descriptive and may be affected by selection and unblinding.
Safety and tolerability
Across the clinical development program, 1,279 patients received at least one dose of tavapadon; 870 were treated for at least six months and 630 for at least one year. Adverse reactions and discontinuation rates differed between the early-disease studies and the adjunctive-levodopa study.
| Use |
Most common adverse reactions at 5 percent or more |
Discontinuation due to adverse reaction |
| Without levodopa |
Nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, anxiety |
20 percent with tavapadon; 85 percent of discontinuations occurred during titration or dose adjustment |
| With levodopa |
Nausea, dyskinesia, dizziness, headache, hallucinations, orthostatic hypotension |
17 percent with tavapadon; 88 percent of discontinuations occurred during titration or dose adjustment |
Warnings and precautions
- Hypotension and orthostatic hypotension may occur, particularly during dose escalation. Monitor for symptoms and counsel patients to rise slowly.
- Impulse control and compulsive behaviors can occur. Ask patients and caregivers specifically about gambling, sexual urges, uncontrolled spending, and binge or compulsive eating.
- Hallucinations and psychotic-like behavior can occur. Older age increases the risk (patients 65 years and older: 4% with tavapadon versus 0% with placebo in the early-disease studies; 9% versus 1% in the adjunctive-levodopa study). Co-administration with strong CYP3A inhibitors during maintenance may also increase the risk. The label advises weighing risks and benefits before starting tavapadon in patients with a major psychotic disorder.
- Tavapadon may cause or worsen dyskinesia. Dose reduction of tavapadon or another dopaminergic medication may be needed.
Clinical perspective
Juvmo provides a once-daily dopamine agonist option across different stages of Parkinson disease. Without levodopa, the TEMPO trials showed improvement in MDS-UPDRS Part II (placebo-adjusted differences of -1.5 to -2.6 points). Added to levodopa, tavapadon increased ON time without troublesome dyskinesia by approximately 1.1 hours more than placebo.
Its D1 and D5 selectivity distinguishes tavapadon from established D2 and D3 dopamine agonists. However, the FDA label still includes class-relevant warnings for orthostatic hypotension, impulse control problems, hallucinations, and dyskinesia. Treatment requires a six-week titration, and most adverse-reaction discontinuations occurred during titration or dose adjustment. Direct comparative trials and broader postmarketing experience will be needed to determine whether receptor selectivity produces a clinically meaningful tolerability advantage.
Key point: Tavapadon is the first FDA-approved selective D1 and D5 partial agonist for adults with Parkinson disease. In early disease it improved activities of daily living (MDS-UPDRS Part II), and added to levodopa it increased ON time without troublesome dyskinesia. Careful titration and monitoring for dopaminergic adverse effects remain necessary.
Sources
1. FDA Novel Drug Approvals for 2026
2. Juvmo prescribing information, revised September 2026
3. FDA approval letter for NDA 220415
4. Michael J Fox Foundation overview, September 25, 2026
5. AbbVie announcement and TEMPO trial summary, September 28, 2026